Walvax Biotechnology Co., Ltd. (SHE:300142)

Walvax Biotechnology Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	3,623	4,365	3,873	3,443	1,962	2,381
Cash & Short-Term Investments	3,623	4,365	3,873	3,443	1,962	2,381
Cash Growth	-11.35%	12.68%	12.49%	75.54%	-17.62%	-4.15%
Accounts Receivable	2,715	3,101	3,577	2,481	2,004	512.84
Other Receivables	81.02	166.15	416.13	774.86	304.77	217.19
Receivables	2,796	3,267	3,993	3,255	2,308	730.03
Inventory	908.62	1,035	995.81	873.59	483.56	313.05
Other Current Assets	70.19	67.24	86.25	107.94	26.77	19.41
Total Current Assets	7,398	8,733	8,948	7,680	4,780	3,444
Property, Plant & Equipment	4,005	3,768	3,161	2,604	1,590	1,389
Long-Term Investments	985.73	1,057	1,292	1,491	1,605	862.27
Goodwill	33.66	33.66	33.66	33.66	33.66	33.66
Other Intangible Assets	1,013	1,086	1,167	434.98	271.68	127.04
Long-Term Deferred Tax Assets	96.28	103.44	124.84	168.01	138.55	91.61
Long-Term Deferred Charges	507.18	473.48	309.38	1,022	890	883.92
Other Long-Term Assets	965.07	333.54	300.2	240.63	329.41	186.97
Total Assets	15,004	15,589	15,336	13,674	9,638	7,018
Accounts Payable	1,505	1,805	1,836	1,258	607.79	276.74
Accrued Expenses	29.82	776.63	1,189	754.71	497.41	45.88
Short-Term Debt	220.16	320.27	97.18	310	40	-
Current Portion of Long-Term Debt	42.49	8.79	-	-	-	-
Current Portion of Leases	-	21.88	23.35	4.6	-	-
Current Income Taxes Payable	13.63	14.13	19.47	2.03	68.54	32.97
Current Unearned Revenue	43.38	42.47	66.78	35.29	9.68	-
Other Current Liabilities	535.82	214.66	276.22	870.61	198.55	732.88
Total Current Liabilities	2,390	3,204	3,509	3,235	1,422	1,088
Long-Term Debt	449.31	434.9	314.24	-	-	-
Long-Term Leases	13.22	20.6	27.74	1.06	-	-
Long-Term Unearned Revenue	283.12	423.33	404.53	344.3	256.18	223.14
Long-Term Deferred Tax Liabilities	65.07	68.71	90.94	94.56	112.27	40.16
Other Long-Term Liabilities	73.03	42.08	-	-	-	-
Total Liabilities	3,274	4,194	4,346	3,675	1,790	1,352
Common Stock	1,599	1,607	1,607	1,601	1,546	1,537
Additional Paid-In Capital	4,549	4,900	4,965	4,772	3,262	2,755
Retained Earnings	3,224	2,984	2,580	1,895	1,546	573.19
Treasury Stock	-	-358.63	-286.42	-	-	-
Comprehensive Income & Other	217.18	217.18	217.18	216.33	190.88	-
Total Common Equity	9,590	9,349	9,084	8,484	6,545	4,865
Minority Interest	2,140	2,046	1,906	1,515	1,303	800.8
Shareholders' Equity	11,730	11,395	10,990	9,999	7,848	5,666
Total Liabilities & Equity	15,004	15,589	15,336	13,674	9,638	7,018
Total Debt	725.17	806.42	462.51	315.67	40	-
Net Cash (Debt)	2,898	3,558	3,411	3,128	1,922	2,381
Net Cash Growth	-17.98%	4.31%	9.06%	62.77%	-19.30%	8.32%
Net Cash Per Share	1.81	2.22	2.13	1.99	1.23	1.55
Filing Date Shares Outstanding	1,599	1,599	1,601	1,601	1,546	1,537
Total Common Shares Outstanding	1,599	1,599	1,601	1,601	1,546	1,537
Working Capital	5,008	5,529	5,440	4,445	3,358	2,355
Book Value Per Share	6.00	5.85	5.67	5.30	4.23	3.16
Tangible Book Value	8,543	8,230	7,883	8,016	6,239	4,704
Tangible Book Value Per Share	5.34	5.15	4.92	5.01	4.04	3.06
Buildings	-	948.5	767.91	541.68	487.84	461.58
Machinery	-	2,093	1,580	1,235	930.76	744.39
Construction In Progress	-	1,645	1,509	1,527	762.51	699.23

Source: S&P Global Market Intelligence. Standard template. Financial Sources.